Immunotherapy for recurrent ovarian cancer may extend the survival time of patients

Recurrent ovarian cancer may reoperation Health, will be right recurrent ovarian cancer surgery and chemotherapy again whether there has been significant controversy. Fourth Militar...

Ovarian cancer is laying? Currently, the incidence rates of ovarian cancer accounts for gynecologic malignancy in 23% ~ 27% as the world's five largest high cance...

Wagner, the German pair of recurrence of ovarian cancer a mouse monoclonal anti-idiotypic antibody immune ACA125 consolidation therapy (tumor-associated antigen CA125 simulation) research. The results confirmed that the treatment of patients with prolonged survival.

The consolidation of the three lines I or Phase II clinical study of 42 cases were included with cisplatin in the treatment of recurrent ovarian cancer after patients. Immunological Methods: start an injection every two weeks at Alum precipitation anti-idiotypic antibodies ACA125 2 mg, a total of four times. Then at a monthly injection. In 56 months of the period and found no serious allergic reaction. 42 cases of patients in 27 cases (64.2%) of the super-human anti-mouse sera showed higher antibody levels. 28 cases (66.7%) patients can detect specific anti - anti-idiotypic antibodies antibody (induced immune markers). ACA125 treatment group patients received an average of 12.6 times after injection of antibodies, the survival of the whole group of patients (14.9 ± 12.9 months). Immunoreactive patients, survival time (19.9 ± 13.1 months); The negative immune response in patients with survival period only (5.3 ± 4.3) months (P <0.0001). (Clin Cancer Res 2001,7:1112)

Based on the above findings, the researchers believe that an appropriate anti-idiotypic antibodies for vaccination is not the original immunogenicity of tumor antigen CA125 induce specific immune as an effective way to extend patients with recurrent ovarian cancer survival, and the small side. Researchers believe that we should do further Phase III clinical study, after initial treatment, anti-idiotypic antibodies for immunotherapy.

The prognosis and outcome: Common and prognosis factors: • clinical stage and is closely related to survival; • histological type and grade pathology and prognos...

Complete remission after isolation of patients with recurrent ovarian cancer viable again cytoreductive surgery Denmark Gronloud such report, as paclitaxel plus platinum chemotherapy after complete remission in patients with ovarian cancer, if recurren...

Experience with ovarian cancer Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect cer...

Ovarian cancer prognosis and outcome Ovarian cancer The prognosis and outcome Common and prognosis factors: • clinical stage and is closely related to survival; • his...

Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates gene...

Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplati...

P53 gene can cure ovarian cancer

Common symptoms of ovarian cancer diagnosis and